Such adverse effects highlight the importance of careful patient selection when prescribing GLP1RA, including identifying those with prior gastrointestinal issues such as severe constipation, prior bowel obstruction or ileus
Why In News
Prader-Willi Syndrome Drug Market Heats Up: 5 Upcoming Challengers to Solenos VYKAT XR Since the FDA approved recombinant human growth hormone (rhGH) for Prader-Willi syndrome (PWS) in 2000, several companies have encountered difficulties in developing more effective therapies for hyperphagia, the persistent and uncontrollable hunger associated with the disorder
While an occasional drink is generally safe for most people, there are specific times during your treatment when you should avoid alcohol entirely: During dose escalation: When you first start the medication or step up to a higher dose, your digestive system is highly sensitive
The guide provides a structure for Australian and New Zealand primary health practitioners, gastroenterologists, surgeons, endocrinologists, anaesthetists and perioperative physicians to support clinical decisions in these patients
Sustained Weight Loss with GLP-1 Receptor Agonist Therapy The Lancet Diabetes & Endocrinology 6
